|Bid||15.00 x 0|
|Ask||15.32 x 0|
|Day's Range||14.96 - 16.64|
|52 Week Range||14.76 - 34.30|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.00|
Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously announced date for publication was March 24, 2023. The change in date is due to prolonged audit of the financial reporting in the European Single Electronic Format, ESEF.
The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Tuesday 18 April 2023, at 16.00 pm in Orexo's facilities at Rapsgatan 7E in Uppsala, Sweden.
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid overdose. OX124, is based on Orexo´s drug delivery platform amorphOX® and contains a high-dose of naloxone.